Can systemic resveratrol improve periodontal treatment outcomes in smokers?

Evidence-based Dentistry published a commentary on a double-blind, placebo-controlled trial by Lucchesi et al. (Clin Oral Invest 2025). Thirty-eight adult smokers with Stage III or IV, Grade C periodontitis received full-mouth ultrasonic debridement plus either systemic resveratrol 500 mg/day or placebo for 180 days, 19 per group. Follow-up ran 12 months. The resveratrol group had significantly lower probing depth and better clinical attachment level than placebo throughout follow-up. At 12 months, probing depth was 2.80 mm in the resveratrol group. The finding is about gum healing in smokers, not aging or lifespan. The trial is small (n=38), single-dose, and the commentary format adds distance from the raw data. For a longevity reader, the useful takeaway is narrow: 500 mg/day systemic resveratrol changed a clinical inflammatory outcome in one small dental trial, which is consistent with resveratrol having measurable anti-inflammatory effects at that dose, but says nothing about longevity endpoints.

Compared with placebo, the resveratrol group demonstrated significantly lower PD and improved CAL throughout follow-up.